What is Haemonetics's apheresis — total long-lived assets?

Haemonetics (HAE) reported apheresis — total long-lived assets of $244.09M in Q2 2026.

What does apheresis — total long-lived assets mean?

This metric measures the total book value of the apheresis segment's non-current assets, including property, plant, equipment, and other long-term investments. It represents the capital base deployed to support the segment's manufacturing, research, and distribution capabilities. Tracking these assets is essential for understanding the scale of the segment's operations and its long-term capital allocation strategy.

Haemonetics (HAE) Apheresis — Total long-lived assets

Screener

Other segment segments

MedSurg

$59.69M—

Similar metrics at other companies

SIGOther — Total long-lived assets

$2.5M-13.8%

AAONBasX — Total long-lived assets

$92.33M+8.8%

PPCEurope — Total long-lived assets

$1.01B+2.2%

PPCMexico — Total long-lived assets

$382.63M+45.5%

PPCU.S. — Total long-lived assets

$2.5B+15.9%

WInternational — Total long-lived assets

$262M-8.7%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:NoncurrentAssets.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	June 27, 2026	March 28,2026
Apheresis	$244,089	$246,042
MedSurg	59,689	59,719
Total long-lived assets	$303,778	$305,761

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's apheresis — total long-lived assets?: Haemonetics (HAE) reported apheresis — total long-lived assets of $244.09M in Q2 2026.
What does apheresis — total long-lived assets mean?: This metric measures the total book value of the apheresis segment's non-current assets, including property, plant, equipment, and other long-term investments. It represents the capital base deployed to support the segment's manufacturing, research, and distribution capabilities. Tracking these assets is essential for understanding the scale of the segment's operations and its long-term capital allocation strategy.